Neurotech International Limited (NTI:ASX) Neurotech director liable of misconduct

Neurotech’s strategic adviser, Dr. Adrian Attard Trevisan, has been found guilty of misconduct after the Malta Times published an article suggesting he never completed a PhD in neuroscience.

Dr. Adrian Attard Trevisan has admitted to his wrong-doing, stating he mislead the public and has never completed a PhD in Neuroscience, from the University of College London. But instead, Dr. Attard Trevisan has a completed PhD in Human Physiology from the University of Milan.

As a result, Dr. Adrian Attard Trevisan has resigned, as the director of Neutrotech Limited, in June 2018 and no longer has any involvment with the company and its board or management team.

“Neurotech’s flagship product Mente is the result of much more than the work of one person. Neurotech’s dedicated Mente team has worked for many years to create, refine and improve the device and its therapeutic outcomes – and that work continues today, and into the future,” Neurotech International Limited.

Please find announcement attached: https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvTDYD4Qq0yhKZruNwke92GA%3D%3D

Fri, 26 Apr	Close	Change
4:50pm	7,575.9	107
Closed at Fri, 26 Apr 6:22pm

S&P/ASX Sm. Ords.	2,964.9	36.8	1.23%
All Ordinaries	7,837.4	100	1.26%
S&P/ASX 100	6,359.6	90.1	1.40%

RCR	RINCON RESOURCES LIMITED	6.9¢	68.3%
VNL	VINYL GROUP LTD	13.0¢	35.4%
ASE	ASTUTE METALS NL	5.4¢	31.7%

MXO	MOTIO LTD	1.5¢	34.8%
PPL	PUREPROFILE LTD	1.6¢	23.8%
OPL	OPYL LIMITED	1.6¢	23.8%

Neurotech director liable of misconduct

Health Care, The Market Herald

NTI by the numbers

ResMed spikes on robust results and global growth spurt

PharmAust CEO’s sayanora triggers stock plunge

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M